gilead sciences nasdaqgild locked heated battle abbvie inc nyseabbv market share hepatitis c treatment battle gone years taken big toll gilead sciences pricing power profits
week gilead sciences announced latest strategy avoid racing 0 pricing hepatitis c products beginning next year two topselling hepatitis c drugs go generic years theyre set lose patent protection
gilead sciences hepatitis c research development gamechanging company launched first hepatitis c drug sovaldi 2014 disease required 48 weeks treatment produced little 50 chance functional cure furthermore prior treatment regimens included sideeffectladen adjunct therapies ribavirin peginterferon making regimens even taxing patients
instead sovaldi ushered era treatments tossed aside need ribavirin peginterferon reduced patient treatment duration little eight weeks people delivered functional cure rates nearly 100
revolutionary treatments came steep cost gilead sciences first treatments launched list prices 100 per pill launched epclusa advanced hepatitis c therapy 2016 list price nearly 7500
hepatitis c cause lifethreatening liver failure alternative treatment options burdensome low cure rates millions people hepatitis c gilead sciences drugs became instant megablockbusters peak selling nearly 20 billion annualized rate
didnt take long competitors notice eager capture fair share market abbvie merck co nysemrk launched competitive solutions slightly lower price points forcing gilead sciences lower prices maintain market share
merck eventually dropped battle abbvie remained last year launched mavyret competitive product yet mavyret matched gilead sciences functional cure rates reduced treatment little eight weeks patients removed need test genotypes determine best course treatment lower cost gilead sciences advanced drugs
given shifting landscape price cutting hard understand gilead sciences sales fallen considerably since competition heated space companys hepatitis c sales tumbled peak annualized pace quarterly pace 1 billion second quarter 2018 29 billion q2 2017
unlike many products drugs carry prices anything transparent
drugmakers create list prices drugs negotiate rebates payers via competitive process cause pay medicine exchange favorable placement drug formularies determine drugs reimbursed customers lowest costsharing levels drugmakers offer even better rebates largest payers like insurers government programs selfinsured companies creating even bigger dislocations marketplace
many payers including individuals pay cash government programs hamstrung rules prevent negotiating lowest price possible drugmakers dont benefit directly current pricing approach additionally price changes hurt inventory underwriting assumptions contracts payers drug companies create supplychain barriers keep prices higher otherwise might
price complexity brings us gilead sciences latest decision compete hepatitis c
beginning january 2019 new subsidiary asegua therapeutics llc sell generic versions hepatitis c drugs list price 2400 common treatment course generics get reimbursement code thereby allowing companies sell existing inventory prices originally intended also giving payers lowercost treatment alternative perhaps biggest beneficiaries scheme managed medicaid programs dont currently reap benefits associated rebates negotiated thirdparty administrators
gilead sciences 2400peryear price tag drugs sell afterrebate basis price shouldnt put much downward pressure gilead sciences sales profit 2019 fact decision unleashes pentup demand payers including medicaid systems volume growth could provide tailwind companys top line bottom line next year
however wouldnt expect abbvie going roll cede back market gilead sciences especially since abbvies hepatitis c sales 973 million second quarter suspect abbvie already working competitive response gilead sciences announcement investors want watch battle shakes terms prescription volume coming quarters
overall intriguing test case drugmakers might embrace maintain market share highly competitive indications dont expect much gilead sciences financials beyond stabilizing hepatitis c revenue drugs return topline bottomline growth
